Figure S1 from Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer

Figure S1 from Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer

<p>Recurrence per PDL1 and MPR</p>

Furkejuvvon:
Bibliográfalaš dieđut
Váldodahkki: Samuel Rosner (15054884) (author)
Eará dahkkit: Joshua E. Reuss (15054887) (author), Marianna Zahurak (15054890) (author), Jiajia Zhang (15054893) (author), Zhen Zeng (15054896) (author), Janis Taube (15054899) (author), Valsamo Anagnostou (14961731) (author), Kellie N. Smith (15054902) (author), Joanne Riemer (15054905) (author), Peter B. Illei (15054908) (author), Stephen R. Broderick (15054911) (author), David R. Jones (15044613) (author), Suzanne L. Topalian (15031475) (author), Drew M. Pardoll (14953549) (author), Julie R. Brahmer (15054914) (author), Jamie E. Chaft (14937195) (author), Patrick M. Forde (15054917) (author)
Almmustuhtton: 2025
Fáttát:
Cancer
Immuno-oncology
Clinical Research and Trials
Clinical Trial Results
Immunotherapy
Checkpoint blockade
Lung Cancer
Fáddágilkorat: Lasit fáddágilkoriid
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
Lasit vuosttaš kommeantta. Visot kommeanttat leat almmolaččat.!
Čálihuva vuohččan sisa

Geahča maid